Dysregulated cell growth or differentiation due to misexpression of developmental critical factors seems to be a decisive event in oncogenesis. As osteosarcomas are histologically defined by malignant osteoblasts producing an osteoid component, we prospected in pediatric osteosarcomas treated with OS94 protocol the genomic status of several genes implied in ossification processes. In 91 osteosarcoma cases, we focused on the analysis of the fibroblast growth factor receptors (FGFRs) TWIST, APC, and MET by allelotyping, real-time quantitative polymerase chain reaction, gene sequencing, and protein polymorphism study. Our study supports the frequent role of TWIST, APC, and MET as osteosarcoma markers (50%, 62%, and 50%, respectively). TWIST and MET were mainly found to be deleted, and no additional APC mutation was identified. Surprisingly, FGFRs are abnormal in only < 30%. Most of these factors and their abnormalities seem to be linked more or less to one clinical subgroup, but the most significant correlation is the link of MET, TWIST, and APC abnormalities to a worse outcome and their combination within abnormal tumors. A wider cohort is mandatory to define more robust molecular conclusions, but these results are to be considered as the beginning of a more accurate basis for diagnosis, in search of targeted therapies, and to further characterize prognostic markers. Neoplasia (2007) 9, [678][679][680][681][682][683][684][685][686][687][688] 
Introduction
Osteogenesis is a complex and coordinated process involving several intricate signaling pathways, as well as many transcription factors. In the 10 past years, the understanding of skeletogenesis has made tremendous advances due to progress in genetic abnormality diagnoses, mice skeletogenesis studies, and cultured osteoblast or chondroblast models. Bone differentiation occurs both by intramembranous ossification, which concerns flat bones of the skull and the lateral part of clavicles, and by endochondral ossification, which concerns the entire appendicular and axial skeleton [1, 2] . Intramembranous ossification is characterized initially by the local proliferation of mesenchymal cells, followed by osteoblast differentiation and local osteogenesis [3, 4] . As a more complex process, endochondral ossification needs initially calcified cartilage cores as rigid scaffold, followed by a vascularization step of this cartilage structure and ended by a process of cartilage resorption concomitantly to bone production [5, 6] . Skeletal elements derive mainly in the head from neural crests; in limbs, they originate from lateral plate mesoderm, whereas axial skeleton is formed from somites [2] .
Disorders caused by mutations in organogenesis are expected to affect skeletal elements in a generalized fashion, whereas mutations in early patterning genes might target only specific elements. Thus, mutations in TWIST, MSX2, and FGFR1 -FGFR3 genes alter more specifically the dynamics of the ossification of cranial sutures [3, 4, 7] , whereas SOX9, bone morphogenetic proteins (BMPs), fibroblast growth factors (especially FGF2), FGFR3, PTHrP and its receptor (PPR), Indian HedgeHog (IHH ), and vascular endothelial growth factor (VEGF ) are some of the genes acting in multistep long bone development [8 -12] . Factors such as Cbfa1 or Fgf2 are known to have a role in both processes [13] . FGF2 has been described to upregulate Twist expression during the mesenchymal proliferation of intramembranous ossification [3, 4] , but it also interacts with Hgf and its receptor Met, promoting chondrocyte differentiation and seemingly increasing osteoblast proliferation rate through this pathway, during endochondral osteogenesis [14] . One of the other common markers is Fgfr3, acting at the osteogenic front of intramembranous process [4] and also playing a role in preformed cartilage [9] . The other example is the canonical Wnt -b-catenin -APC pathway, which has been recently implicated in osteoblast lineage differentiation in both types of ossifications [15] and which contributes to repressing chondrocyte gene expression during skeletogenesis through Twist signaling [16] . Most of these factors are upregulated or downregulated at different check points of normal development to act through a signaling network of dorsal -ventral specification and mesoderm determination. For example, upregulation of Twist is involved in mesoderm cell proliferation, whereas downregulation of this protein implies osteoblastic differentiation [1 -3] .
These osteogenesis signaling pathways are especially active during embryogenesis and postnatal bone development, but their aberrant activation or suppression can lead also to development of cancers in differentiated tissues. For example, fibroblast growth factor receptors (FGFRs) [17 -21] , as well as TWIST [22 -24] or canonical Wnt signaling that has been well studied in colon carcinoma multistep oncogenesis [25] , had been frequently described as progression markers in several cancers. Some of these biomarkers, such as the Twist or the Wnt -b-catenin -APC pathway, are also known to have a high rate of proliferative effect on cancer cells with inhibition of apoptotic signals [23, 25] . In high-grade osteosarcoma characterized by the presence of malignant osteoblasts and the production of osteoid component, it could then be hypothesized that such markers could play a role in multistep tumorigenesis. As concerns specifically this malignant bone tumor, only a few of these markers, such as BMPs, FGFR4, PTHrP, MET, or TWIST, had been proven to be involved [20,21,26 -30] . In addition, the recent development of biphosphonate, particularly targeting PTHrP in osteosarcomas and based on mice model and in vitro results [31 -33] , confirmed experimentally the interest of using new treatments targeting ossification functions in this cancer.
Therefore, understanding fundamental and developmental ossification processes will probably help to unravel bone cancer oncogenesis as it will pinpoint pathways whose alterations contribute to malignant bone tumor onset and progression. Furthermore, identifying new marker genes with disordered expression in cancer might be a putative target for new therapeutic agents.
Then, to gain insight into ossification pathways in bone cancers, our work focused previously on three markers, namely, APC, MET, and TWIST genes and loci in a clinically well-known pediatric population of 91 high-grade osteosarcomas [29, 30] . These previous studies showed striking results correlating most of these markers to a worse outcome or to poor response to chemotherapy. They also showed a significant correlation between deletion at TWIST and APC region rearrangements [30] . Based on these promising results and because of close interactions in both ossification processes, the status of FGFR1 -FGFR4 genes was also analyzed at DNA level. Then, the first step of this screening was performed by using microsatellites surrounding MET, APC, and TWIST genes to confirm the high percentage of these loci abnormalities found in our previous work. Complementary real-time quantitative polymerase chain reaction (QPCR) targeting MET, TWIST, and FGFR (FGFR1 -FGFR3) genes was performed concomitantly to the sequencing of an APC mutation cluster region to understand the role and alterations of these targeted genes. As one specific single nucleotide polymorphism (SNP) of FGFR4 gene (G!A), resulting in Gly388Arg substitution [19, 20, 27, 34] , was described as a marker of progression and invasion in several cancers, we investigated both the genotype status of our cohort on codon 388 and the copy number of FGFR4 by QPCR. All these molecular results were finally correlated with clinical and histologic features characterizing this homogeneous pediatric population.
Methods

Population, Tumor Banking, and DNA Isolation
Ninety-one pediatric primary high-grade osteosarcomas, treated homogeneously with OS94 protocol and followed from November 1994 to June 2006, were included in this molecular study. The entire study was performed in accordance with the Declaration of Helsinki. The clinical and histologic characteristics of this population are detailed in Table 1 , and most of them were used for statistical correlations. Most of these patient data had been already described in our previous works and recently updated [29, 30] .
Frozen tumor biopsies were collected from each child at diagnosis, before any treatment. They were stored at À80jC. Because they were dedicated mainly for histologic diagnosis, only small tumor samples were obtained, allowing only assessable DNA extraction for these 91 patients. Control tissue was also obtained from peripheral blood and conserved on Whatman paper at room temperature. Tumor and blood paired DNA were purified as already described in previous publications [29, 30, 35] . Tumor and blood DNA concentrations, quantified by fluorometry, ranged from 50 to 400 ng/ml and from 1 to 10 ng/ml, respectively.
Allelotyping of 5q21, 7p21, and 7q31 Loci
These 91 paired normal and tumor DNA were investigated by allelotyping with two microsatellites surrounding the APC gene in 5q21 (D5S346 and D5S492), four microsatellites surrounding the TWIST gene in 7p21 (centromeric D7S2495 and D7S2559; telomeric D7S1683 and D7S2532), and two microsatellites surrounding the MET gene in 7q31 (D7S486 and D7S677 ) (see primer description at http://www.ncbi.nlm. nih.gov/genemap99 and http://www.gdb.org Web sites). As previously described [29, 30] , DNA from both paired samples were amplified by fluorescent PCR, which was performed in an Omnigen Hybaid Thermocycler (Hybaid Ltd., Ashford, UK) using the following protocols: 5 minutes at 95jC, 35 cycles of 1 minute at 95jC, 1 minute at 55jC (D5S346, D5S492, D7S2495, D7S2559, D7S1683, D7S2532, and D7S677 ) or 53jC (D7S486), and 1 minute at 72jC, followed by 5 minutes at 72jC. PCR products, after separation with denaturing urea gel on a sequencer (Amersham Pharmacia Biotech, Uppsala, Sweden), were directly detected and quantified using an Alfwin Fragment Analyzer software package (Amersham Pharmacia Biotech, Uppsala, Sweden). In the last samples, allelotyping was performed using the automated 3100 Applied Biosystems (Foster City, CA) combining microsatellites in multiplex PCRs. This highly reproducible and sensitive technique is devoted to detecting two genomic abnormalities: microsatellite instability (MSI) in case of the presence of additional peaks in tumor samples compared to blood DNA, and allelic imbalance (AI) characterized by the modification of the allele ratio in tumor DNA linked to chromosome instability. MSI is the witness of a mismatch repair defect or RER phenotype, whereas AI detects both locus deletion and locus amplification without precision on the real state of the locus. The intensity of AI is calculated as follows:
, where B a and B b represent the height of two alleles in control blood, and T a and T b represent the height of two alleles in the tumor. The significant cutoff of allelic variation was set above 20% [35] . Each result was confirmed by a duplicate PCR.
Real-Time QPCR of MET, TWIST, and FGFR1 -FGFR4
Six genes (MET, TWIST, FGFR1, FGFR2, FGFR3, and FGFR4) were quantified by QPCR using SYBR Green I dye (Roche Molecular Biochemicals, Mannheim, Germany) with Light Cycler technology (Roche Molecular Biochemicals). Primer sequences were chosen to target introns of each specific gene and are summarized in Table 2 . The two internal control genes DCK and APP, localized at loci 4q13.3 -21.1 and 21q21, respectively, were those used on TWIST in the same tumor collection in our previous work [30] . The thermal cycle conditions for the six target and two reference genes were exactly the same as previously described [30] . For each experiment, in addition to tumor DNA, a calibrator sample, a normal control DNA, and a negative control were amplified. QPCR was performed in duplicate for tumor samples. Result 
analyses, using the Light Cycler software version 3.5 (Roche Molecular Biochemicals), were based on the following relative calculation:
CP is the number of cycles for which a fluorescent product could be measured just above a fluorescent noisy background. For each couple of target/reference genes, a cohort of 20 normal samples was investigated to determine the confidence interval and standard deviations of calculated ratios. Established normal cutoffs are detailed in Table 2 .
PCR Restriction Fragment Length Polymorphism Analysis of FGFR4
This analysis is based on the detection of SNP variant in codon 388 of the FGFR4 gene (located in exon 9). Exon 9 of FGFR4 was amplified by PCR using the following primer set: forward primer 5V-GACCGCAGCAGCGCCCGAGGCC-AG-3V and reverse primer 5V-AGAGGGAAGCGGGAGAGC-TTCTGC-3V [20] . The PCR protocol was as follows: a denaturation step of 94jC for 5 minutes, 35 cycles of 94jC for 1 minute, 64jC for 1 minute, and 72jC for 1 minute, and a final extension step of 72jC for 10 minutes. Then, these PCR products were prepared for digestion with the restriction enzyme BstNI (New England Biolaboratories, Beverly, MA) and separated with a 4% agarose gel containing ethidium bromide. Electrophoresis allowed us to distinguish between fragment lengths corresponding to Gly allele at codon 388 (109 bp) and fragment lengths corresponding to Arg allele (fragments of 80 and 29 bp). Direct sequencing, using a 3100 automated ABI sequencer (Applied Biosystems), was also performed to confirm the genotype on PCR products in a majority of cases.
APC Mutation Analysis
PCR amplification of the APC mutation cluster region (codons 1286-1513) was performed on tumor samples using five couples of sense and antisense primers, localized from codons 1200 to 1700 and summarized in Table 3 . Purified PCR fragments were then directly sequenced in both directions using the BigDye sequencing kit and a 3100 automated ABI sequencer following the manufacturer's instructions (Applied Biosystems, Foster City, CA). In each mutated sample, a duplicate experiment will be required to confirm the mutation in two independent amplification products of the same sample.
Statistical Analysis
The association with clinical and histologic parameters described in Table 1 was examined using Pearson's chi-square test. Survival curves and correlations with survival outcome for each molecular marker were performed according to KaplanMeier and used log-rank statistics. Statistical significance was determined in case of P V .05. All statistical tests were performed using SPSS 11.5 (SPSS, Inc., Chicago, IL).
Results
These 91 children and teenagers are representative of the whole population treated with OS94 protocol in terms of clinical characteristics and therapeutic results (Table 1 ) [36] , allowing us to consider this tumor collection as one of the larger homogeneous pediatric osteosarcoma banks. With data updates, the overall survival (OS) in our population is 77%, and event-free survival (EFS) is 60.2% at 5 years. Furthermore, response to chemotherapy was statistically significant for OS (P = .004) and EFS (P = .06). Thirty-six of the 91 patients included in this molecular study relapsed, and their median time to relapse was 29 months after diagnosis (range, 2 -102 months).
Ossification Markers Are Significantly Involved in Pediatric High-Grade Osteosarcomas
As previously published [29, 30] , loci 7q31, 7p21, and 5q21 are frequently rearranged by allelotyping. As there were only few discordant results between microsatellites of the same locus (1 of 91 for MET region; 3 of 76 for TWIST region; and 2 of 91 for APC locus), we could process the following analysis, and patients considered as informative for these loci either were heterozygous for both markers (D7S486/D7S677, D7S2495/D7S2532, and D5S346/D5S492) or presented with one altered or normal zygosity and with homozygosity at the second marker. In case of homozygous results for D7S2495/ D7S2532 surrounding the TWIST locus, we did consider, in addition, the results of two more distant microsatellites D7S2559 and D7S2532. No MSI was observed, and AI was found in 52% (37 of 71) for locus 7q31 containing MET, in 46.9% (38 of 81) for locus 7p21 containing TWIST, and in 62.3% (48 of 77) for locus 5q21 containing APC. Looking closely at the gene status itself by QPCR, MET was normal in 50% (44 of 88), deleted in 41% (36 of 88), and amplified in 9% (8 of 88) ( Table 4) . Three patients were not included in our analysis because two tumor DNA could not be amplified with MET primers, and the other one was homozygous by allelotyping and had discordant results with the two control genes (normal with MET/APP and deleted with MET/DCK ). Table 3 . Primers for APC Gene Sequencing.
Forward Primers
Reverse Primers Codons Nucleotides 5V-GTAAGCCAGTCTTTGTGTC-3V  5V-CAGCTGATGACAAAGATGAT-3V  1125 -1284  3378 -3852  5V-AGACTTATTGTGTAGAAGATAC-3V  5V-ATGGTTCACTCTGAACGGA-3V  1260 -1410  3780 -4230  5V-TCTGTCAGTTCACTTGATAG-3V  5V-CAT TTGATTCTTTAGGCTGC-3V  1389 -1547  4167 -4641  5V-ACAGAAAGATGTGGAATTAAG-3V  5V-TTCTCCAGCAGCTAACTCAT-3V  1516 -1673  4548 -5019  5V-GCTACATCTCTAAGTGATCT-3V 5V-CTTATCATTGAAGTCCTTGG-3V 1654 -1826 4962 -5478 TWIST, as already published [30] , was normal in 50% (37 of 74), deleted in 36.5% (27 of 74), and amplified in 13.5% (10 of 74) (Table 4) . Results by real-time QPCR are matched with allelotyping in 58 of 71 informative patients for MET, and in 64 of 68 initially informative patients for TWIST. Deletion or amplification was detected in 4 of 4 discordant results with TWIST QPCR, and in 6 of 13 discordant results with MET QPCR, allowing us to conclude for these genes and primers that the QPCR technique, as previously described, is less sensitive than allelotyping.
No additional APC mutation in the mutation cluster region was detected in the normal population by allelotyping, and neither was there in the rearranged subgroup.
QPCR targeting FGFR1 -FGFR4 revealed surprisingly low rates of abnormalities (20%, 23%, 16%, and 30%, respectively). When rearranged, FGFR1 -FGFR3 are more often deleted (11%, 21%, and 9%, respectively), whereas FGFR4 is slightly more often rearranged (30%) and mainly amplified (24%; 19 of 81 assessable tumors). Complementary analysis of SNP in FGFR4 at codon 388 revealed Gly/ Gly homozygosity in 54.7% tumors (41 of 75), Gly/Arg heterozygosity in 25.3% (19 of 75), and Arg/Arg homozygosity in 20% (15 of 75).
Statistical analyses combining the results of the different markers (Figures 1 and 2 ) showed significant links between TWIST deletion and loss of heterozygosity (LOH) at the APC locus (P = .04), as already published [30] , between TWIST and MET deleted subsets (P = .023), and a tendency between TWIST amplification and FGFR2 deletion (P = .11). A higher frequency of Arg allele in Fgfr4 protein polymorphism was also shown with TWIST amplification. Surprisingly, when cross-table analyses were performed, no MET amplification was found to be associated with FGFR1, FGFR2, FGFR3, or FGFR4 amplification, and the highest rate of normal FGFR populations, especially for FGFR1, was found in this specific MET subgroup. Furthermore, a METamplified subset was not correlated to TWIST, neither to the PDGFRA amplification previously described in our population [37] . MET amplification was found in only one case associated with KIT amplification (data previously published in Entz-Werle et al. [37] ). MET deletion was associated with the highest percentage of APC (5q21) alterations. If we consider our previously published data on P53, RB, and P16 loci [29] , no real differences were observed for TWIST alterations, but in MET alterations, a link between a rearranged RB1 and MET amplification (P = .06), and between a normal 9p21 locus containing P16 and this amplified subset was obvious.
Do These Markers Characterize Clinical Subgroups?
Our analysis also aimed to prospect the potential predictive value of each marker in different subgroups of pa- Figure 1 . Gene status within TWIST subgroups and statistical combinations. For each gene, we considered the proportion of normal and abnormal subpopulations in each TWIST subgroup (i.e., normal TWIST, TWIST deletion, and TWIST amplification patients). Black circles underline the main associations.
tients, namely, localized tumor versus metastatic disease at diagnosis, no relapse versus relapse(s), the number of relapses, good responders (GR subgroup) versus poor responders (PR subgroup) to chemotherapy, alive versus deceased, histopathological subsets (osteoblastic, fibroblastic, and chondroblastic subtypes), and locations of primary tumor. The main cross-table statistical analyses are summarized in Table 4 .
Metastatic osteosarcomas (14 children), especially in the smaller subgroup of deceased metastatic patients (9 children), are significantly characterized by a higher rate of TWIST abnormalities (67% and 75%, P = .05 and .04, respectively) and a higher range of TWIST amplification. This subgroup also tends to be linked to APC rearrangement with 89% of 5q21 rearrangements. Neither FGFR2 nor FGFR3 was rearranged in deceased metastatic patients, and no FGFR deletions were observed. As concerns FGFR4 polymorphism, the Arg/Arg 388 genotype is significantly absent in the metastatic subgroup (P = .02).
Interestingly, significant statistical links were observed in relapsed tumors with TWIST abnormalities (69%, predominantly deleted; P = .03) and MET abnormalities (70%, also predominantly deleted; P = .004), but in a higher percentage of normal FGFR3 (94%; P = .08) and FGFR4 (83%; P = .05) genes. In case of abnormalities in these genes, they are mainly deleted, and no case of amplified FGFR3 was found in the relapse population. The number of relapses (among 36 relapses, 4 patients relapsed twice) did not matter to molecular profiles. Considering the response to chemotherapy, no significant statistical data distinguishing the GR subgroup from the PR subgroup were found. The only noticeable result is the increase in TWIST (56% vs 46%) and APC (71% vs 58%) abnormalities, normal FGFR3 gene percentage (89% vs 79%), and absence of amplification cases at FGFR2 in the GR subgroup. Comparing molecular profiles between still-alive patients and deceased children, statistically significant trends link a high frequency of TWIST and MET deletions (P = .01 and P = .03), a more frequent APC rearrangement (P = .03), and a normal FGFR3 gene (P = .07) to the deceased population. Due to the small size of the fibroblastic and chondroblastic histologic subgroups, the following observations might not be statistically significant. However, we observed in chondroblastic osteosarcomas, known to be more aggressive tumors [36] , that the FGFR1 and FGFR3 genes are perfectly normal, that there is no FGFR2 amplification or FGFR4 deletion, and that MET is mainly amplified. The fibroblastic subset had also noticeable higher frequencies of FGFR1 and FGFR3 gene abnormalities and MET gene abnormality. Finally, considering tumor locations, 12 humerus osteosarcomas are significantly characterized by TWIST deletion (seven deleted tumors of eight rearranged tumors) (P = .01), whereas among 58 lower-limb osteosarcomas, 34 of 58 were normal, 16 of 58 had TWIST deletion, and 8 of 58 presented TWIST amplification.
The Prognostic Significance of Differentiating Factors APC, TWIST, and MET remain as prognostic markers in pediatric osteosarcoma biopsies, as already published [29, 30] . Indeed, TWIST deletion and amplification are significantly linked to a worse outcome (P = .026 for EFS; P = .019 for OS) (Figures 3A and 4A) . MET abnormalities are also significant witnesses of poor EFS, especially MET amplification (P = .015; Figure 3B ), and tend to be linked to a worse OS (P = .10; Figure 4B ), whereas APC rearrangement tends only to be correlated to a worse EFS (P = .15; Figure 3C ) and is correlated to a worse OS (P = .035; Figure 4C ). No significant correlation was established for FGFR genes.
Discussion
Ossification Factors Are Involved in Pediatric High-Grade Osteosarcomas
That rearrangements in APC, TWIST, and MET genes are detected in around half of the pediatric osteosarcoma population strongly point toward a role for these ossification factors in pediatric osteosarcoma oncogenesis. Unlike other cancers that are mainly described as overexpressing c-Met or Twist proteins [22 -24,38 -41] , these genes are mostly deleted in pediatric osteosarcomas (three quarters of abnormal tumors for TWIST and MET presented deletions). Sixtytwo percent of D5S346/D5S492 AI could be also considered as LOH because we used D5S346 to target the APC locus, which is relevant to diagnosing APC LOH in colon cancers [42] . As described above, the decrease in TWIST, APC, and MET expressions is involved in normal bone production [1, 3, 4, 15, 16, 43] . Such observation could explain why gene deletions in osteosarcoma are detected because undifferentiated and malignant osteoblasts usually produce an osteoid or a bone component. A significant combination of these deletions, linking TWIST and MET deletions and APC alterations, was observed. This subgroup of TWIST or MET deletion seems to need additional deleted genes to deregulate differentiation to obtain a malignant osteoblast status. However, TWIST or MET amplification, described as a proliferative cancer factor [22 -24] , does not need the upregulation of another biomarker to allow osteoblast proliferation (Figures 1 and 2) . The links between this combination of TWIST, MET, and APC genes seems to be widely explained through interactions during normal ossification [15, 16, 43] . In addition, the decrease in APC and MET expression is specifically dedicated to endochondral ossification to decrease chondrocyte component and explains the slight increase in MET-amplified tumors in our chondroblastic subpopulation [4, 43] . Furthermore, the higher number of TWIST-amplified chondroblastic tumors might be also explained by the role of TWIST-increased expression during the intramembranous ossification process [3, 4] . All these rearrangements suggest a greater role in ''osteogenic'' profile rather than a role in progression phenotype, as described by Patane et al. [44] for c-Met.
In contrast, FGFR1 -FGFR4, although documented as implied in bone growth and/or differentiation, appear only to be rearranged in about 16% to 30% of osteosarcomas. Both deletion and amplification are found in these pediatric osteosarcomas (FGFR1, FGFR2, and FGFR3 are mainly deleted, and FGFR4 is amplified) and have also been described in several adult cancers. For example, Fgfr3 protein is Figure 3 . EFS correlations considering TWIST (A), MET (B), and APC (C) molecular abnormalities. A statistical correlation for TWIST and MET analyses is found between a worse outcome and rearranged populations, and only a tendency for APC study.
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overexpressed in hepatocarcinoma [45] , whereas the expression is lost in higher grades and stages of bladder cancers [46] . Loss of FGFR2 has already been described in osteosarcomas [21] and brain tumors [47] , whereas Fgfr4 protein has been mainly overexpressed in adult cancers [48] . As less rearranged genes, FGFRs do not appear as major specific markers in this pathology. However, FGFRs, which are involved in late bone differentiation [1, 2, 4] , seem to modulate osteosarcoma oncogenesis, in addition to the main combination of MET, TWIST, and APC alterations. Indeed, FGFR2 deletion is significantly associated with a TWIST-amplified subgroup, whereas the absence of alterations in FGFR1-FGFR3 is frequently observed in the MET-amplified subset (Figures 1 and 2 ). As described in calvarial formation, Twist upregulation and Fgfr2 downregulation are concomitantly observed [1, [4] [5] [6] . Considering the FGFR results in Table 4 , no alterations could be associated with an aggressive subtype of pediatric osteosarcoma. From the point of view of the osteogenesis process, no statistically significant correlations for FGFR genes and histologic subgroups could be found. However, hyperactivation of these receptors was usually involved during normal bone production of endochondral ossification and fusion of cranial sutures [1, 2] , and such observation could explain the absence of any FGFR1 -FGFR3 amplifications in chondroblastic histologic subtypes (Table 4) .
Ossification Markers, Progression Factors, and/or Survival Biomarkers Multiple progression factors, which have been previously described in other cancers, were analyzed in this study [19, 20, 22, 23] as TWIST, MET, and APC genes or Fgfr4 protein polymorphism. Most of them are frequently altered in our homogeneously treated population of pediatric osteosarcomas. Concerning FGFR4 genotyping, different percentages (compared to the study of Morimoto et al. [27] on bone tumors and soft-tissue sarcomas) were shown. In our population (Table 4) , most of the tumors (54.7%) are characterized by a Gly/Gly FGFR4 genotype, whereas in the bone tumor subgroup of Morimoto et al., which combined pediatric and adult patients and multiple types of bone malignancies, most of them showed an Arg/Gly FGFR4 genotype (49%). If we compare our results to the published control series by Bange et al. [20] , Morimoto et al. [27] , or Wang et al. [48] , our cohort seems to be quite different, with a higher frequency of Arg/Arg FGFR4 genotype (19.7%), usually linked to an increased mobility in mammary tumor cell lines [20] , and a lower subgroup of Arg/Gly FGFR4 genotype (25.8%), usually linked to early metastasis in colon cancers [24] .
Looking closely at our statistical analyses, significant gene correlations seem to characterize patients who were diagnosed initially with a more agressive disease (metastatic patients) and those who progressed after diagnosis (tumor relapses). First of all, one marker is common to both patient subgroups: TWIST alteration. We observed predominantly deletions in relapses and deletion or amplification in metastatic populations. Considering our results, which are summarized in Table 4 , the molecular profile of an initial metastatic osteosarcoma could be an abnormal TWIST gene with a normal FGFR2 gene (P = .07) and no Arg/Arg FGFR4 genotype (P = .02), modulated toward a worse outcome by an APC alteration (P = .07). During relapse, another molecular profile combining predominant TWIST (P = .03) and MET deletions (P = .004) and normal FGFR3 and FGFR4 genes (P = .08 and P = .05, respectively) seems to be highlighted. Among these markers, abnormal APC and MET genes are probably the differential factor witnesses of initial invasiveness versus later progression. Surprisingly, but concordant with previous conclusions [27] , FGFR4 genotype at codon 388 had no impact on late progression but seemed to have a role in initial metastatic disease.
The major altered genes TWIST, MET, and APC and their combination are also found to be significantly linked to a worse outcome, as exemplified by statistics in alive and deceased subpopulations and survival analyses. Indeed, some of these factors are involved in patient outcome and could be considered as prognostic markers. TWIST deletions and amplifications seem to have the same worst outcome consequence, whereas MET-amplified tumors are doing worse than those that are deleted. In fact, patients characterized by a MET-amplified tumor would only have a 5-year EFS of 28% and a 5-year OS of 53% ( Figures 3B and 4B ). This last statement lets us hypothesize that detection of MET abnormalities could also subgrade the whole worse outcome group and select the worst subset of patients. The major difficulty in both amplified populations is the low number of tumors, which does not allow us to complete significant analyses. However, these altered subpopulations for TWIST and MET genes are characterized by differential molecular profiles, as shown in Figures 1 and 2 . TWIST deletion seems to be associated with MET deletion and APC alteration, whereas TWIST amplification is linked to FGFR2 deletion and Arg/Arg Fgfr4 protein polymorphism. Conversely, MET amplification seems to be associated with normal FGFRs and RB1 and with an increase in the number of 9p21 locus alteration. No clinical factors seem to be associated with MET amplification, except for increase in chondroblastic histology, which is usually linked to a worse outcome [36] . For FGFR genes, to date, no evident links between outcome and those genes have been described because of small abnormal populations. A study on a larger population would probably be able to define their precise role in osteosarcoma survival.
Could These Factors Be Potential Therapeutic Targets and/or Used as Routine Biomarkers?
Furthermore, MET and FGFR code for tyrosine kinase receptors, which are therapeutic targets of recently developed drugs. Most of these recent treatments inhibit multiple receptors such as SU006668 or PTK787, targeting, namely, VEGFR, PDGFR, FGFR, or MET [49, 50] . Our findings of multiple DNA amplifications, leading probably to hyperexpression of wild-type receptors, could promote the use of these new therapeutic strategies. Even though FGFR rearrangements are less frequent and amplification is rarer than deletion, all these findings could help us to refine accurately the subgroup of patients who are able to respond to these new drugs, targeting the same signaling pathways at multiple levels. Furthermore, the rapid, sensitive, and useful techniques described in this study could be used routinely to analyze the status of these genes as surrogate biomarkers at diagnosis on biopsies in pediatric osteosarcomas.
Another therapeutic involvement for these analyses could be an ability to predict a worse clinical outcome at diagnosis, allowing us to stratify the high-risk group of pediatric osteosarcoma cases that should be treated by new strategies to intensify present treatment. Thus, defining molecular profiles of patients would be a helpful tool to determine therapeutic strategies that fit each critical patient and to grade osteosarcomas.
To summarize, our findings further expand knowledge on the role of ossification factor in homogeneous pediatric osteosarcomas. Much more than being involved in the oncogenesis of pediatric osteosarcomas, these factors are also new witnesses to tumor progression and invasiveness and to a worse outcome group. Their combination seems to be the key to further understanding osteosarcoma oncogenesis. To confirm these interesting data, this molecular analysis should be performed on a larger prospective group to obtain significantly statistical analyses in FGFR gene studies.
